Bladder cancer occurs mainly in older people over the age of 55, with the average age of diagnosis around 73. Women are less likely to be diagnosed with bladder cancer and men are about three to four times more likely to be diagnosed with the disease.
Transitional cell carcinoma is the most common type of bladder cancer. Squamous cell carcinoma, adenocarcinoma, and small cell carcinoma are the other less common types of bladder cancer.
Why choose the Mays Cancer Center for bladder cancer?
Our multidisciplinary team led by genitourinary (GU) oncologists, urologists, medical oncologists and radiation oncologists work together to create the ideal treatment plan for patients. We are the only National Cancer Institute (NCI) designated cancer center in Central and South Texas and have an extensive network of clinical trials to meet patients’ needs.
Our genitourinary team holds regular tumor boards that include pathologists who specialize in bladder pathology. Your treatment plan is developed after these comprehensive evaluations and discussion. We partner with the National Cancer Institute and other organizations for clinical trial-based treatment options for all patients.
The cancer center offers care delivered by teams who specialize in all phases of clinical trials. Clinical trials are available to patients of all stages of treatment, from early diagnosis through existing therapies.
As a National Cancer Institute (NCI) designated cancer center, the cancer center also offers experimental treatments and first-in-human clinical trials under special programs for patients.
Make an appointment
To request an appointment with our team or to make a referral to one of our physicians, please call the main number: 210-450-1000 or 800-340-2872 or email CTRCReferral@uthscsa.edu.